2m 2m 2m 2m 2m 2m 2m
Alnylam Pharma (ALNY)
NASDAQ
$227.53+$2.43 (+1.08%)
Price as of Oct 22, 2026 7:54 PM EDT- $30.1BMarket Cap
- -51.58%1-Year Change
- BiotechnologyIndustry
Alnylam Pharma (ALNY)
$227.53+$2.43 (+1.08%)
ALNY | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $225.10 | ||
Change | -$5.61 (-2.43%) | ||
Open | $227.86 | ||
High | $230.84 | ||
Low | $224.88 | ||
Previous Close | $230.71 | ||
Volume | 1,181,022 | ||
30-Day Average Volume | 1,248,352 | ||
1-Week Change | 0.28% | ||
1-Month Change | -7.87% | ||
1-Year Change | -51.58% | ||
3-Year Change | 39.13% | ||
5-Year Change | 10.16% | ||
Fundamentals | |||
Shares Outstanding | 133.8M | ||
Total Assets | $5.6B | ||
Market Cap | $30.1B | ||
Enterprise Value | $29.4B | ||
Period: QTR TTM FY | |||
Revenue | $1.2B | ||
Net Income | $164.5M | ||
Free Cash Flow | $292.0M | ||
EBIT | $177.8M | ||
EBITDA | $191.7M | ||
Net Working Capital | $3.1B | ||
EPS | $1.21 | ||
Enterprise Value/EBITDA | 153 | ||
Enterprise Value/Revenue | 25 | ||
P/B | 22 | ||
P/E | 186 | ||
PEG | -9 | ||
Price/Free Cash Flow | 103 | ||
Price/Operating Cash Flow | 92 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue